Cargando…
High serum PD‐L1 level is a poor prognostic biomarker in surgically treated esophageal cancer
BACKGROUND: Programmed death ligand 1 (PD‐L1) inhibitor has been approved as one of the standard therapies for various cancers. Some reports have shown that serum PD‐L1 level is associated with advanced tumor stages and poor prognosis; however, corresponding pathological information in esophageal ca...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7013049/ https://www.ncbi.nlm.nih.gov/pubmed/31865635 http://dx.doi.org/10.1002/cam4.2789 |
_version_ | 1783496332339576832 |
---|---|
author | Ito, Masaaki Yajima, Satoshi Suzuki, Takashi Oshima, Yoko Nanami, Tatsuki Sumazaki, Makoto Shiratori, Fumiaki Funahashi, Kimihiko Tochigi, Naobumi Shimada, Hideaki |
author_facet | Ito, Masaaki Yajima, Satoshi Suzuki, Takashi Oshima, Yoko Nanami, Tatsuki Sumazaki, Makoto Shiratori, Fumiaki Funahashi, Kimihiko Tochigi, Naobumi Shimada, Hideaki |
author_sort | Ito, Masaaki |
collection | PubMed |
description | BACKGROUND: Programmed death ligand 1 (PD‐L1) inhibitor has been approved as one of the standard therapies for various cancers. Some reports have shown that serum PD‐L1 level is associated with advanced tumor stages and poor prognosis; however, corresponding pathological information in esophageal cancer patients is lacking. Therefore, we evaluated the clinicopathological and prognostic impact of serum PD‐L1 levels in surgically treated esophageal cancer. METHODS: A total of 150 patients who underwent radical resection for esophageal cancer were included in the study. Preoperative serum PD‐L1 levels were analyzed using the enzyme‐linked immunosorbent assay kit. A cutoff level of 65.6 pg/mL was used to divide the patients into two groups, and univariate and multivariate analyses were conducted to compare the clinicopathological characteristics and prognoses between these two groups. RESULTS: Although significant associations between serum PD‐L1 levels and clinicopathological variables were observed, serum PD‐L1 level was significantly associated with high neutrophil counts, high CRP levels, low albumin levels, and high squamous cell carcinoma antigen levels. Furthermore, serum PD‐L1 level was associated with poor overall survival independent to TNM factors. CONCLUSIONS: High preoperative level of serum PD‐L1 is a prognostic factor for poor overall survival in patients with surgically treated esophageal cancer. |
format | Online Article Text |
id | pubmed-7013049 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-70130492020-03-24 High serum PD‐L1 level is a poor prognostic biomarker in surgically treated esophageal cancer Ito, Masaaki Yajima, Satoshi Suzuki, Takashi Oshima, Yoko Nanami, Tatsuki Sumazaki, Makoto Shiratori, Fumiaki Funahashi, Kimihiko Tochigi, Naobumi Shimada, Hideaki Cancer Med Clinical Cancer Research BACKGROUND: Programmed death ligand 1 (PD‐L1) inhibitor has been approved as one of the standard therapies for various cancers. Some reports have shown that serum PD‐L1 level is associated with advanced tumor stages and poor prognosis; however, corresponding pathological information in esophageal cancer patients is lacking. Therefore, we evaluated the clinicopathological and prognostic impact of serum PD‐L1 levels in surgically treated esophageal cancer. METHODS: A total of 150 patients who underwent radical resection for esophageal cancer were included in the study. Preoperative serum PD‐L1 levels were analyzed using the enzyme‐linked immunosorbent assay kit. A cutoff level of 65.6 pg/mL was used to divide the patients into two groups, and univariate and multivariate analyses were conducted to compare the clinicopathological characteristics and prognoses between these two groups. RESULTS: Although significant associations between serum PD‐L1 levels and clinicopathological variables were observed, serum PD‐L1 level was significantly associated with high neutrophil counts, high CRP levels, low albumin levels, and high squamous cell carcinoma antigen levels. Furthermore, serum PD‐L1 level was associated with poor overall survival independent to TNM factors. CONCLUSIONS: High preoperative level of serum PD‐L1 is a prognostic factor for poor overall survival in patients with surgically treated esophageal cancer. John Wiley and Sons Inc. 2019-12-21 /pmc/articles/PMC7013049/ /pubmed/31865635 http://dx.doi.org/10.1002/cam4.2789 Text en © 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Cancer Research Ito, Masaaki Yajima, Satoshi Suzuki, Takashi Oshima, Yoko Nanami, Tatsuki Sumazaki, Makoto Shiratori, Fumiaki Funahashi, Kimihiko Tochigi, Naobumi Shimada, Hideaki High serum PD‐L1 level is a poor prognostic biomarker in surgically treated esophageal cancer |
title | High serum PD‐L1 level is a poor prognostic biomarker in surgically treated esophageal cancer |
title_full | High serum PD‐L1 level is a poor prognostic biomarker in surgically treated esophageal cancer |
title_fullStr | High serum PD‐L1 level is a poor prognostic biomarker in surgically treated esophageal cancer |
title_full_unstemmed | High serum PD‐L1 level is a poor prognostic biomarker in surgically treated esophageal cancer |
title_short | High serum PD‐L1 level is a poor prognostic biomarker in surgically treated esophageal cancer |
title_sort | high serum pd‐l1 level is a poor prognostic biomarker in surgically treated esophageal cancer |
topic | Clinical Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7013049/ https://www.ncbi.nlm.nih.gov/pubmed/31865635 http://dx.doi.org/10.1002/cam4.2789 |
work_keys_str_mv | AT itomasaaki highserumpdl1levelisapoorprognosticbiomarkerinsurgicallytreatedesophagealcancer AT yajimasatoshi highserumpdl1levelisapoorprognosticbiomarkerinsurgicallytreatedesophagealcancer AT suzukitakashi highserumpdl1levelisapoorprognosticbiomarkerinsurgicallytreatedesophagealcancer AT oshimayoko highserumpdl1levelisapoorprognosticbiomarkerinsurgicallytreatedesophagealcancer AT nanamitatsuki highserumpdl1levelisapoorprognosticbiomarkerinsurgicallytreatedesophagealcancer AT sumazakimakoto highserumpdl1levelisapoorprognosticbiomarkerinsurgicallytreatedesophagealcancer AT shiratorifumiaki highserumpdl1levelisapoorprognosticbiomarkerinsurgicallytreatedesophagealcancer AT funahashikimihiko highserumpdl1levelisapoorprognosticbiomarkerinsurgicallytreatedesophagealcancer AT tochiginaobumi highserumpdl1levelisapoorprognosticbiomarkerinsurgicallytreatedesophagealcancer AT shimadahideaki highserumpdl1levelisapoorprognosticbiomarkerinsurgicallytreatedesophagealcancer |